Hepatoblastoma Treatment Study

Clinical Trial Title

Treatment of children with all stages of hepatoblastoma with temsirolimus (IND#122782, NSC#683864) added to high risk stratum treatment.

Clinical Trial Protocol Description:

A risk-based treatment approach will maintain or improve event-free survival (EFS), decrease acute and long-term chemotherapy toxicity, and identify new agents in the treatment of children with hepatoblastoma.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are less than 21 years of age at the time of diagnosis.
  • Have been newly diagnosed with histologically-proven hepatoblastoma.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Mary Lou Schmidt, MD

Contact Information

Nitin Sane

(312) 355-0741